Jim Simons Bio Cardia, Inc. Transaction History

Renaissance Technologies LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$0.37 - $1.07 $28,786 - $83,246	77,800 Added 740.95%	88,300 $59,000
Q3 2023 Nov 14, 2023	SELL	$0.37 - $2.85 $2,664 - $20,520	-7,200 Reduced 40.68%	10,500 $5,000
Q2 2023 Aug 11, 2023	BUY	$1.52 - $2.8 $3,192 - $5,880	2,100 Added 13.46%	17,700 $47,000
Q1 2023 May 12, 2023	BUY	$1.87 - $2.54 $2,805 - $3,810	1,500 Added 10.64%	15,600 $30,000
Q4 2022 Feb 13, 2023	SELL	$1.61 - $32.1 $322 - $6,420	-200 Reduced 1.4%	14,100 $29,000
Q3 2022 Nov 14, 2022	SELL	$0.24 - $30.3 $120 - $15,150	-500 Reduced 3.38%	14,300 $28,000
Q2 2022 Aug 12, 2022	BUY	$17.7 - $32.55 $19,470 - $35,805	1,100 Added 8.03%	14,800 $21,000
Q1 2022 May 13, 2022	BUY	$21.3 - $39.0 $291,810 - $534,300	13,700 New	13,700 $28,000
Q4 2021 Feb 11, 2022	SELL	$25.65 - $46.05 $1.12 Million - $2.01 Million	-43,549 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$42.6 - $58.65 $2.5 Million - $3.44 Million	-58,681 Reduced 57.4%	43,549 $137,000
Q2 2021 Aug 13, 2021	SELL	$48.9 - $74.85 $9.93 Million - $15.2 Million	-202,970 Reduced 66.5%	102,230 $406,000
Q1 2021 May 13, 2021	BUY	$51.3 - $78.15 $15.7 Million - $23.9 Million	305,200 New	305,200 $1.33 Million

Ticker BCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,758,200
Market Cap $39.8M
Description
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary di...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.